

# Pharmacokinetics of pegylated interferons: What is mis

Digestive and Liver Disease

36, S334-S339

DOI: [10.1016/s1590-8658\(04\)80002-1](https://doi.org/10.1016/s1590-8658(04)80002-1)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Factors of importance for a successful delivery system for proteins. Expert Opinion on Drug Delivery, 2005, 2, 1029-1037.	5.0	35
2	Second thoughts about secondary analyses. Digestive and Liver Disease, 2005, 37, 805-807.	0.9	0
3	Nanotechnology: A Focus on Nanoparticles as a Drug Delivery System. Journal of NeuroImmune Pharmacology, 2006, 1, 340-350.	4.1	222
4	Peptide and Protein Drugs: Issues and Solutions. , 2007, , 573-601.		8
5	Hepatitis C Treatment of Opioid Dependents Receiving Maintenance Treatment: Results of a Norwegian Pilot Study. European Addiction Research, 2007, 13, 216-221.	2.4	43
6	PEGylation of cholecystokinin prolongs its anorectic effect in rats. Peptides, 2007, 28, 1003-1011.	2.4	17
7	Pegylated IFN- $\beta$ plus ribavirin for treatment-naive patients coinfecting with HCV and HIV. Expert Review of Anti-Infective Therapy, 2008, 6, 281-289.	4.4	5
8	Novel Controlled-Release <i>Lemna</i> -Derived IFN- $\beta$ (Locteron): Pharmacokinetics, Pharmacodynamics, and Tolerability in a Phase I Clinical Trial. Journal of Interferon and Cytokine Research, 2008, 28, 113-122.	1.2	74
9	Pharmacotherapy of chronic hepatitis C virus infection – the IDEAL trial: $\beta$ or not $\beta$ (= 2a), that is the question™. Expert Opinion on Pharmacotherapy, 2009, 10, 2845-2857.	1.8	6
10	HBV and HCV Therapy. Viruses, 2009, 1, 484-509.	3.3	7
12	Pegylated IFN- $\alpha$ 2a and ribavirin in the treatment of hepatitis C. Expert Review of Anti-Infective Therapy, 2009, 7, 925-935.	4.4	19
13	Treatment with PEG-interferon and Ribavirin for Chronic Hepatitis C Increases Neutrophil and Monocyte Chemotaxis. Annals of the New York Academy of Sciences, 2009, 1173, 847-857.	3.8	11
14	Peg-Interferon in Acute and Chronic Hepatitis C: A Review. American Journal of Therapeutics, 2009, 16, 573-578.	0.9	15
15	Persistent interferon transgene expression by RNA interference-mediated silencing of interferon receptors. Journal of Gene Medicine, 2010, 12, 739-746.	2.8	8
17	Pegylated interferons $\alpha$ 2a and $\alpha$ 2b in the treatment of chronic hepatitis C. Nature Reviews Gastroenterology and Hepatology, 2010, 7, 485-494.	17.8	62
18	Pegylated interferon and ribavirin treatment for hepatitis C virus infection. Therapeutic Advances in Chronic Disease, 2011, 2, 39-45.	2.5	63
19	Peginterferon- $\alpha$ 2B plus ribavirin is more effective than peginterferon- $\alpha$ 2A plus ribavirin in menopausal women with chronic hepatitis C. Journal of Viral Hepatitis, 2012, 19, 640-649.	2.0	8
20	Exploring a new jellyfish collagen in the production of microparticles for protein delivery. Journal of Microencapsulation, 2012, 29, 520-531.	2.8	39

#	ARTICLE	IF	CITATIONS
21	Evaluation of the Absolute Bioavailability of Pegylated Interferon Alfa-2a After Subcutaneous Administration to Healthy Male Volunteers: An Open-Label, Randomized, Parallel-Group Study. <i>Clinical Therapeutics</i> , 2012, 34, 1883-1891.	2.5	6
22	Comparative trials of peginterferon $\hat{1}\pm 2a$ and peginterferon $\hat{1}\pm 2b$ for chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , 2012, 19, 37-41.	2.0	7
23	Results of Treatment of Chronic Hepatitis B with Pegylated Interferon. <i>Clinics in Liver Disease</i> , 2013, 17, 425-443.	2.1	6
24	Why do I treat HBeAg $\hat{e}$ negative chronic hepatitis B patients with pegylated interferon?. <i>Liver International</i> , 2013, 33, 157-163.	3.9	17
25	PegIFN- $\hat{1}\pm 2a$ for the treatment of chronic hepatitis B and C: a 10-year history. <i>Expert Review of Anti-Infective Therapy</i> , 2013, 11, 459-474.	4.4	15
26	Saturable human neopterin response to interferon- $\hat{1}\pm$ assessed by a pharmacokinetic-pharmacodynamic model. <i>Journal of Translational Medicine</i> , 2013, 11, 240.	4.4	6
27	Type I Interferons: Ancient Peptides with Still Under-Discovered Anti-Cancer Properties. <i>Protein and Peptide Letters</i> , 2013, 20, 412-423.	0.9	12
28	Differential Antiviral Effects of Pegylated Interferon- $\hat{1}\pm 2a$ and Pegylated Interferon- $\hat{1}\pm 2b$ in Chronic Hepatitis C. <i>Clinical Drug Investigation</i> , 2014, 34, 871-878.	2.2	0
29	Viral Hepatitis C Therapy: Pharmacokinetic and Pharmacodynamic Considerations. <i>Clinical Pharmacokinetics</i> , 2014, 53, 409-427.	3.5	35
30	Potential of Pegylated Interferon Alpha-2a in Beh $\hat{A}$ set Uveitis: A Report of Five Cases. <i>Ocular Immunology and Inflammation</i> , 2015, 24, 1-4.	1.8	13
31	A phase 2 trial of long-acting TransCon growth hormone in adult GH deficiency. <i>Endocrine Connections</i> , 2017, 6, 129-138.	1.9	24
32	The rationale and design of TransCon Growth Hormone for the treatment of growth hormone deficiency. <i>Endocrine Connections</i> , 2017, 6, R171-R181.	1.9	40
33	A first-in-man phase 1 trial for long-acting TransCon Growth Hormone. <i>Growth Hormone and IGF Research</i> , 2018, 39, 34-39.	1.1	14
34	Cytokine Therapeutics in Cancer Immunotherapy: Design and Development. <i>Current Pharmacology Reports</i> , 2019, 5, 377-390.	3.0	4
35	Long-Term Efficacy of Pegylated Interferon Alpha-2b in Beh $\hat{A}$ set $\hat{e}$ ™s Uveitis: A Small Case Series. <i>Ocular Immunology and Inflammation</i> , 2019, 27, 15-22.	1.8	16
36	Safety, Immune, and Antiviral Effects of Pegylated Interferon Alpha 2b Administration in Antiretroviral Therapy-Suppressed Individuals: Results of Pilot Clinical Trial. <i>AIDS Research and Human Retroviruses</i> , 2021, 37, 433-443.	1.1	9
37	Comparable HIV suppression by pegylated-IFN- $\hat{1}\pm 2a$ or pegylated-IFN- $\hat{1}\pm 2b$ during a 4-week analytical treatment interruption. <i>Aids</i> , 2021, 35, 2051-2054.	2.2	0
38	Effect of Different Interferon $\hat{1}\pm 2$ Preparations on IP10 and ET-1 Release from Human Lung Cells. <i>PLoS ONE</i> , 2012, 7, e46779.	2.5	13

#	ARTICLE	IF	CITATIONS
39	Nanomedicines in the treatment of patients with hepatitis C co-infected with HIV ? focus on pegylated interferon-alpha. International Journal of Nanomedicine, 2006, 1, 399-409.	6.7	3
40	Long-acting Recombinant Human Granulocyte Colony Stimulating Factor (rhG-CSF) with a Trimer-Structured Polyethylene Glycol. Journal of Pharmaceutical Investigation, 2010, 40, 379-386.	5.3	1
42	Evaluation of Safety and Pharmacokinetic Behavior of Unipeg® in Healthy Human Volunteers. Journal of Pharmacy and Nutrition Sciences (discontinued), 2014, 4, 220-227.	0.4	0
43	Sudden Deafness in a Patient with Chronic Hepatitis C Treated with Peginterferon and Ribavirin Combination Therapy. Korean Journal of Medicine, 2015, 88, 288.	0.3	0
44	Current Knowledge of Biologics in Treatment of Noninfectious Uveitis. Journal of Ocular Pharmacology and Therapeutics, 2022, 38, 203-222.	1.4	6